Most of What You Call an “Antacid” Isn’t One

Walk down the heartburn aisle and nearly everything on the shelf gets called an antacid. Three of those products work in completely different ways, on completely different clocks. Grab the wrong one and you are choosing between relief in ninety seconds and relief in four days — without the box making that obvious.

What’s actually true: Only the fast-acting neutralizers — Tums, Rolaids, milk of magnesia — are true antacids. The other heavy hitters in that aisle, H2 blockers like famotidine (Pepcid) and proton pump inhibitors (PPIs) like omeprazole (Prilosec), don’t neutralize acid at all. They tell your stomach to make less of it, on timelines that run from about half an hour to several days.

What’s misleading or unregulated: The box rarely says in plain terms which job it does, product names actively blur the line (a box marked “Zantac” today contains a different drug than the Zantac millions of people remember), and the strongest option is designed for a 14-day course yet routinely taken daily for years — which is exactly where the documented risks live.

The three products differ less by strength than by where they interrupt the acid cycle. Your stomach lining is dotted with parietal cells, and those cells run a little acid factory. An antacid, an H2 blocker, and a PPI each hit that factory at a different point — which is why they feel so different in practice even though they all end up as “heartburn medicine” on the same shelf.

An antacid is simply a base. Calcium carbonate, magnesium hydroxide, or aluminum hydroxide neutralizes acid that is already sitting in your stomach, the moment it makes contact. That is why it works within minutes. It is also why the effect fades fast — usually 30 minutes to a couple of hours — because it does nothing to slow the acid your stomach keeps making.

An H2 blocker works one step upstream. Histamine is one of the signals that tells parietal cells to switch on; famotidine and cimetidine block the histamine-2 receptor and turn that signal down, cutting acid output by roughly 70 percent. It kicks in over about 15 to 90 minutes and holds for as long as 8 to 12 hours. Taken before a known trigger meal or at bedtime, it heads off symptoms rather than chasing them.

A PPI works at the very end of the line, at the pump itself. Omeprazole and its cousins shut down the proton pump — the H+/K+ ATPase that physically ejects acid — for up to about 99 percent suppression. The catch is timing: a PPI inactivates pumps gradually, so it can take one to four days to reach full effect and is explicitly not built for immediate relief. Once it is working, one morning dose covers roughly 24 hours. It works best taken 30 to 60 minutes before the first meal, when the most pumps are active and available to bind.

So the practical question is not “which is strongest” but “which clock matches my problem.” Occasional, predictable burn a few times a month, after a known trigger? An antacid is the right tool — fastest on, shortest off. An alginate product such as Gaviscon is a close cousin that forms a floating barrier on top of the stomach contents and is handy after meals. Symptoms a few times a week, or predictable evening flares? An H2 blocker taken ahead of the trigger or at night gives more reliable coverage. Frequent heartburn — two or more days a week for weeks on end? That is the scenario an OTC PPI course is designed for, but it will not touch tonight’s flare, so people often bridge the first few days of a PPI course with an antacid.

Two more things the label will not shout at you. Antacids can blunt the absorption of other medicines — thyroid pills, some antibiotics, certain others — so they are generally separated from those doses by about two hours. And some symptoms are not routine heartburn at all: trouble or pain swallowing, unintentional weight loss, black or tarry stools, persistent vomiting, or chest or shoulder pain with sweating and shortness of breath all warrant a doctor rather than another tablet. That last one can be a heart attack masquerading as indigestion.

The most useful number on a PPI box is one most people ignore: 14 days. The over-the-counter Prilosec OTC label caps a course at 14 days, no more than once every four months, and no more than three courses a year without seeing a doctor. That is not a pharmacology quirk — it is a safety boundary. If two weeks of a PPI does not settle things, the label’s logic is that you might be suppressing the symptom of something that needs looking at, from reflux disease to, rarely, changes in the esophagus that only surface when a clinician goes looking.

The reason that boundary matters is what shows up with long-term use. A string of FDA drug safety communications has linked prolonged PPI use to low magnesium (2011), a possible increase in hip, wrist, and spine fractures (2010–2011), and a higher risk of Clostridioides difficile diarrhea (2012), with vitamin B12 and kidney concerns raised since. Most of these are associations drawn from population data rather than proven cause and effect, and the risk from a short OTC course is low — but they are the reason “PPI for a fortnight” and “PPI for three years, unsupervised” are genuinely different propositions. Stopping abruptly after long use can also trigger a rebound in acid, which sends some people straight back for another box.

Then there is the manufacturing story hiding inside a familiar name. In April 2020 the FDA requested that manufacturers withdraw every ranitidine product — the drug sold for decades as Zantac — from the U.S. market. The problem was not the drug’s effect but its chemistry: the agency found that ranitidine forms NDMA, a probable human carcinogen, and that the level climbs the longer the pills sit and the warmer they get, pushing past an acceptable daily limit of 96 nanograms. Ranitidine was an H2 blocker, the same category as Pepcid. Its testing-cleared neighbors — famotidine, cimetidine, omeprazole and the rest — stayed on shelves.

Here is where the marketing gets slippery. Rather than retire a trusted name, the manufacturer relaunched it: “Zantac 360°” now contains famotidine — a different molecule than the ranitidine that made Zantac famous, and the very same active ingredient as Pepcid. The boxes lean on phrases like “new formula” and “now with famotidine.” It is a perfectly legal, arguably safer product; it is also a masterclass in how a brand can survive a recall while the drug underneath it changes entirely. Sellers across the category market on the two things that photograph well — speed (“fast relief”) and duration (“24-hour”) — while the one fact that should drive your choice, the drug class, sits in small type on the back. To their credit, pharmacists and medication-safety groups have been vocal about the Zantac renaming precisely because a shopper who does not read the active-ingredient line can easily assume they are buying what they bought five years ago.

The aisle sells three tools as if they were one. Match the tool to the clock — neutralize now, damp down for the evening, or shut the pump over days — and you have solved most of the problem. The real hazard is not picking wrong once. It is settling onto the strongest option, unsupervised, well past the window it was built for. The honest caveats: most long-term PPI risks are associations rather than proven cause, a newer class of acid drug — the potassium-competitive acid blockers, led by vonoprazan — is beginning to change the options, and whether a genuinely NDMA-free version of ranitidine ever returns to shelves is unsettled. For now, the most important line on the box is the one it is easiest to skip: the active ingredient.

Citations

1. U.S. Food and Drug Administration. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market. April 1, 2020. fda.gov
2. U.S. Food and Drug Administration. Questions and Answers: NDMA impurities in ranitidine (commonly known as Zantac). fda.gov
3. Prilosec OTC (omeprazole magnesium) Drug Facts and prescribing information: 14-day course, once every 4 months, up to 3 courses per year. drugs.com
4. Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Therapeutic Advances in Drug Safety. Summarizes the FDA drug safety communications on hypomagnesemia, fractures, and Clostridioides difficile. pubmed.ncbi.nlm.nih.gov
5. GoodRx Health. Acid Reflux Medicine: Antacids, H2 Blockers, Proton Pump Inhibitors — onset, duration, and where PCABs fit. goodrx.com
6. GoodRx Health. Zantac Overview: the 2021 relaunch of Zantac 360 with famotidine in place of ranitidine. goodrx.com

Disclaimer: This content includes personal opinions and interpretations based on available sources and should not replace medical advice. This content includes interpretation of available research and should not replace medical advice. Although the data found in this blog and infographic has been produced and processed from sources believed to be reliable, no warranty expressed or implied can be made regarding the accuracy, completeness, legality or reliability of any such information. This disclaimer applies to any uses of the information whether isolated or aggregate uses thereof.